- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04246918
Effect of BCAA Supplementation on Muscle Mass, Muscle Quality and Molecular Markers of Muscle Regeneration in CLD Patients (BCAA-CLD)
Effect of Branched Chain Amino Acids Supplementation on Muscle Mass, Muscle Quality and Molecular Markers of Muscle Regeneration in Patients With Chronic Liver Disease - A Randomized Controlled Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Reduction in muscle mass (sarcopenia) is well documented in patients with chronic liver disease (CLD)leading to increased morbidity, mortality and poor quality of life. An equilibrium is maintained between the synthesis and degradation of muscles to maintain the muscle mass. However, an imbalance between the synthesis and degradation leads to loss of muscle mass. Various factors like alteration in dietary intake, hyper-metabolism, changes in amino acid profile, decreased physical activity, endotoxemia, hyperammonemia, increased myostatin levels have been postulated in the pathogenesis of muscle loss in liver disease. Reduced dietary intake, altered amino acid profile, decreased physical activity down regulate the anabolic pathway while the others increase the catabolic pathway. Increased level of myostatin inhibits the mTOR signaling and increases catabolism. Various therapeutic strategies such as increased calorie and protein intake, branched chain amino acid (BCAA) supplementation, late evening snack (LES), increased physical activity are the well accepted therapies. Hormone therapy (testosterone/growth hormone) also has been tried to improve muscle mass and function, reduce muscle catabolism in patients with CLD, however these newer treatment modalities i.e. hormone replacement, immune-nutrition and anti-myostatin antibodies are not free from adverse side-effects. Branched chain amino acids, a group of three essential amino acids (leucine, isoleucine, valine) have been tried since years in the setting of chronic liver disease patients for the treatment of hepatic encephalopathy and improvement in nutritional status. However, the studies assessing the impact of nutrition and BCAA in CLD have not assessed the direct impact on the muscle per se. The nutritional status has been assessed using different subjective methods like mid arm muscle circumference, triceps skin fold, nitrogen balance. Nutritional management is the cornerstone of the overall management of patients with cirrhosis, wherein BCAA constitutes an important therapeutic modality in the realm of nutrition in liver disease.
In the present study all the eligible cirrhotic patients will be randomized to a control group (receiving the nutritional therapy as per the standard nutritional practices and guidelines) or the intervention group (receiving BCAA supplementation over and above the standard nutrition therapy as per the standard nutritional practices and guidelines). Branched chain amino acids (BCAA) have the potential to up-regulate the anabolic pathway of muscle synthesis leading to improvement in muscle mass. Muscle mass as assessed by DEXA, along with changes in muscle histology, markers of the pathways that regulate muscle growth, functional capacity, and quality of life will be assessed after 3 months of BCAA intervention.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Puja Bhatia, MSc
- Phone Number: 8586912966
- Email: pujabhatia27@gmail.com
Study Locations
-
-
Delhi
-
New Delhi, Delhi, India, 110070
- Recruiting
- Institute of Liver and Biliary Sciences
-
Contact:
- Jaya Benjamin, Dr
- Phone Number: 9540951081
- Email: jayabenjaminilbs@gmail.com
-
Contact:
- Puja Bhatia, Ms
- Phone Number: 8586912966
- Email: pujabhatia27@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with decompensated cirrhosis (CTP 7-9)
- Adult patients Age 18-60 years
- Patients with corrected BMI in the range <22.9
- Those who give consent for muscle biopsy
- INR <1.5 or 1.5-2.5 after correction with Vitamin K
- Platelets > 80000
- All etiologies
Exclusion Criteria:
- Presence of overt hepatic encephalopathy
- Patients with co-morbidities e.g. acquired immunodeficiency syndrome, HCC, Other cancer, Diabetes Mellitus, chronic kidney disease, congestive heart disease , chronic respiratory disease
- Patients with alcohol intake in past 3 months
- Patients with TIPS
- Patients on steroids
- INR >2.5
- Refusal to participate in the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Standard Treatment Group
The patients would receive customized diet charts providing 30-35Kcal/ideal body wt/day and 1.5 gm protein/ideal body wt/day) describing the food items along with the quantity and approximate household measurements.
Diet would be so planned for each patient keeping in mind the individual food habits and choices.
This group would not receive any supplement other than the prescribed diet.
Whey protein will be included in this group.
|
Whey protein will be given to the standard treatment arm including in the same amount of 1.5gm/kg/IBW.
|
Active Comparator: Intervention Arm
The patients would receive customized diet charts providing 30-35Kcal/ideal body wt/day and 1.5 gm protein/ideal body wt/day) describing the food items along with the quantity and approximate household measurements.
Diet would be so planned for each patient keeping in mind the individual food habits and choices.
In addition to the normal diet this group would receive 16gm of branched chain amino acid (BCAA) supplement (Commercial oral BCAA granules) daily in 4 divided doses, keeping the protein levels within the same range of 1.5 gm/Kg/day.
|
Branched chain amino acid is a group of three amino acids known for there role in muscle growth.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in the muscle mass
Time Frame: 3 months
|
Muscle mass change as assessed by DEXA scan will be done.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the muscle fibre type composition
Time Frame: 3 months
|
Muscle fibre type will be assessed in muscle biopsy sample
|
3 months
|
Changes in cross sectional area of muscle
Time Frame: 3 months
|
Muscle fibre cross sectional area will be assessed in muscle biopsy sample
|
3 months
|
Assessment of necrosis in muscle fibre
Time Frame: 3 Months
|
Muscle fibre necrosis will be assessed in muscle biopsy sample
|
3 Months
|
Assessment of intramuscular fat deposition
Time Frame: 3 months
|
Change in intramuscular fat deposition will be assessed in muscle biopsy sample.
|
3 months
|
Assessment of myoD
Time Frame: 3 month
|
Change in myoD will be assessed as marker of muscle regeneration in muscle biopsy sample
|
3 month
|
Assessment of myogenin
Time Frame: 3 months
|
Change in myogenin will be assessed as marker of muscle regeneration in muscle biopsy sample
|
3 months
|
Assessment of PCNA
Time Frame: 3 months
|
Change in PCNA as marker of satellite function will be assessed in muscle biopsy sample
|
3 months
|
Assessment of proteosome C3, C5, C9
Time Frame: 3 months
|
Change in these proteosome will be assessed in muscle biopsy sample
|
3 months
|
Assessment of ubiquitin ligase E3
Time Frame: 3 months
|
Change in Ubiquitin ligase E3 will be assessed in muscle biopsy sample.
|
3 months
|
Assessment of myostatin level
Time Frame: 3 months
|
Change in myostatin level will be assessed in blood sample using commercially available kit.
|
3 months
|
Assessment of ammonia level
Time Frame: 3 months
|
Change in ammonia level will be assessed in blood sample using commercially available kit
|
3 months
|
Assessment of Insulin resistance
Time Frame: 3 Month
|
Insulin resistance will be calculated using homeostasis model for insulin resistance.
|
3 Month
|
Assessment of IGF 1
Time Frame: 3 Month
|
IGF1 will be assessed using commercially available kit.
|
3 Month
|
Assessment of Nutritional Status
Time Frame: 3 Month
|
Change Nutritional status will be assessed using bioelectrical impedance analysis
|
3 Month
|
Assessment of Nitrogen balance
Time Frame: 3 Month
|
Change in nitrogen balance will be assessed using formula : Nitrogen Balance = Protein intake (gm) / 6.25 - (UUN + 4 gm)
|
3 Month
|
Assessment of functional capacity
Time Frame: 3 Months
|
The Functional capacity of the patients would be assessed by Hand Grip Strength using the Handgrip Dynamometer .
|
3 Months
|
Assessment of Clinical parameter- CTP
Time Frame: 3 Months
|
Clinical improvement will be assessed in terms of change in CTP score.
|
3 Months
|
Assessment of Clinical parameter-MELD
Time Frame: 3 Months
|
Clinical improvement will be assessed in terms of change in MELD score.
|
3 Months
|
Assessment of Health Related Quality of Life
Time Frame: 3 Months
|
The Health Related Quality of Life (HRQoL) of the patients would be assessed using the Chronic liver disease questionnaire(CLDQ)
|
3 Months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Puja Bhatia, MSc, Institute of Liver and Biliary Sciences
- Study Director: Jaya Benjamin, PhD, Institute of Liver and Biliary Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ILBS-BCAA-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Liver Disease
-
First Affiliated Hospital of Zhejiang UniversityCompletedAcute-On-Chronic Liver Failure | Cirrhosis and Chronic Liver Disease
-
Chuncheon Sacred Heart HospitalSuspendedChronic Liver Disease | Acute Derangement of Liver FunctionKorea, Republic of
-
Assiut UniversityCompletedAcute-On-Chronic Liver FailureEgypt
-
Third Affiliated Hospital, Sun Yat-Sen UniversityWithdrawnLiver Failure, Acute on ChronicChina
-
Beijing 302 HospitalShenzhen Third People's Hospital; Shulan (Hang Zhou) Hospital; BeijingYouan Hospital and other collaboratorsNot yet recruitingAcute-On-Chronic Liver FailureChina
-
Tianjin Weikai Bioeng., Ltd.Tianjin Nankai HospitalUnknownLiver Failure, Acute on ChronicChina
-
Shanghai Jiao Tong University School of MedicineNot yet recruitingChronic Liver Disease and CirrhosisChina
-
Chulalongkorn UniversityRecruitingAcute-On-Chronic Liver Failure | Acute on Chronic Hepatic FailureThailand
-
Daewoong Pharmaceutical Co. LTD.Enrolling by invitationChronic Liver DiseaseKorea, Republic of
-
Meridian Bioscience, Inc.CompletedChronic Liver DiseaseUnited States, Israel
Clinical Trials on Whey Protein concentrate powder
-
University of the Incarnate WordEnrolling by invitation
-
Auburn UniversityCompletedSkeletal Muscle
-
University of LimerickMarigot Ltd.; Enterprise IrelandCompletedBioavailability of Amino Acids Following Oral Ingestion of Plant-Based Proteins in Young, Healthy MenIreland
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); University of California, Davis and other collaboratorsCompletedRegulation of Muscle Protein SynthesisCanada
-
University of LimerickUnknown
-
University College DublinFHI 360Completed
-
Wageningen University and ResearchCompleted
-
Norwegian School of Sport SciencesArkansas Children's Hospital Research Institute; TineCompletedHealthy Participants
-
All India Institute of Medical Sciences, New DelhiCompleted
-
Wageningen University and ResearchCompleted